Treatment change in pregnancy is a significant risk factor for detectable HIV-1 RNA in plasma at end of pregnancy

Marco Floridia, Marina Ravizza, Carmela Pinnetti, Cecilia Tibaldi, Anna Bucceri, Gianfranco Anzidei, Marta Fiscon, Atim Molinari, Pasquale Martinelli, Serena Dalzero, Enrica Tamburrini

Research output: Contribution to journalArticle

Abstract

Purpose: To investigate the risk factors for an HIV-1 RNA plasma viral load above 400 copies/mL in the third trimester of pregnancy. Methods: Data from a large national study were used. The possible determinants were assessed in univariate analyses and in a multivariate logistic regression model in order to adjust for possible confounders. Results: Among 662 pregnancies followed between 2001 and 2008, 131 (19.8%) had an HIV-1 plasma copy number above 400/mL at the third trimester of pregnancy. In the multivariate analysis, the variables significantly associated with this occurrence were earlier calendar year (adjusted odds ratio [AOR] per additional calendar year, 0.70; 95% CI, 0.63-0.77; P <.001), lower CD4 count at enrollment (AOR per 100 cells lower, 1.18; 95% CI, 1.09-1.27; P <.001), HIV-1 RNA levels above 400 copies per mL at enrollment (AOR, 2.23; 95% CI, 1.50-3.33; P <.001), and treatment modification during pregnancy (AOR, 1.66; 95% CI, 1.07-2.57; P = .024). Conclusions: Treatment changes in pregnancy significantly increase the risk of an incomplete viral suppression at the end of pregnancy. In HIV-infected women of childbearing age, proper preconception care, which includes the preferential prescription of regimens with the best safety profile in pregnancy, is likely to prevent an incomplete viral suppression at the end of pregnancy.

Original languageEnglish
Pages (from-to)303-311
Number of pages9
JournalHIV Clinical Trials
Volume11
Issue number6
DOIs
Publication statusPublished - Jan 1 2010

Keywords

  • antiretroviral treatment
  • HIV
  • pregnancy
  • viral load
  • women

ASJC Scopus subject areas

  • Infectious Diseases
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Treatment change in pregnancy is a significant risk factor for detectable HIV-1 RNA in plasma at end of pregnancy'. Together they form a unique fingerprint.

  • Cite this

    Floridia, M., Ravizza, M., Pinnetti, C., Tibaldi, C., Bucceri, A., Anzidei, G., Fiscon, M., Molinari, A., Martinelli, P., Dalzero, S., & Tamburrini, E. (2010). Treatment change in pregnancy is a significant risk factor for detectable HIV-1 RNA in plasma at end of pregnancy. HIV Clinical Trials, 11(6), 303-311. https://doi.org/10.1310/hct1106-303